Top Markets
Coin of the day
MGC Pharmaceuticals Limited MGC Pharmaceuticals Limited

MGC Pharmaceuticals Limited

MXC
Rang in Aktien #39836
MGC Pharmaceuticals Limited, an Australian biopharmaceutical firm established... MGC Pharmaceuticals Limited, an Australian biopharmaceutical firm established in West Perth in 2014, focuses on the worldwide development and distribution of plant-derived medicines. Its product portfolio encompasses both medicinal cannabis solutions and other botanical therapeutics. The company's key investigational treatments include CimetrA, currently in Phase III clinical trials for the symptomatic relief of early-stage COVID-19; CannEpil, a cannabis-based therapy undergoing Phase IIb studies for drug-resistant epilepsy; and CogniCann, which is in Phase II clinical development for alleviating dementia symptoms. Beyond these core candidates, MGC Pharmaceuticals also supplies the ArtemiC range, various other cannabinoid-infused products, and non-pharmaceutical items. Additionally, the company provides expert consulting services, particularly in clinical research. The company was previously named Erin Resources Limited before adopting its current identity, MGC Pharmaceuticals Limited, in December 2015.
Aktienkurs
$0.27239819
Zuletzt synchronisiert: 2024-04-29
Marktkapitalisierung
$330.42K
Veränderung (1 Tag)
0.52%
Veränderung (1 Jahr)
0.00%
Land
AU
Handel MGC Pharmaceuticals Limited (MXC)

Kategorie

EPS für MGC Pharmaceuticals Limited (MXC)
EPS zum 2026 TTM: 0
Laut den aktuellen Finanzberichten und dem Aktienkurs von MGC Pharmaceuticals Limited beträgt das aktuelle EPS des Unternehmens (TTM) 0. Am Ende des Jahres 2026 betrug das EPS 0 gleich wie dem EPS von 2026, das 0 betrug.
EPS-Verlauf von MGC Pharmaceuticals Limited von 2026 bis 2026
EPS am Ende jedes Jahres
Jahr EPS ändert
Nicht genügend Daten für die angegebenen Daten.
EPS für ähnliche Unternehmen oder Wettbewerber